Recent News

• 06.03.2025 - Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
• 04.28.2025 - Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
• 04.24.2025 - Kairos Pharma Ltd. Provides Letter to Stockholders
• 04.17.2025 - Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Recent Filings

• 06.03.2025 - EX-99.1 EX-99.1
• 06.03.2025 - 8-K Current report
• 05.16.2025 - DEFR14A Revised definitive proxy soliciting materials
• 05.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.06.2025 - PRER14A Preliminary Proxy Soliciting materials
• 05.01.2025 - DEF 14A Other definitive proxy statements
• 04.30.2025 - 3 Initial statement of beneficial ownership of securities
• 04.29.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.28.2025 - 8-K Current report